Fulgent Genetics (FLGT) PT Lowered to $6.00 at Credit Suisse Group
Several other analysts also recently issued reports on FLGT. Zacks Investment Research upgraded Fulgent Genetics from a strong sell rating to a hold rating in a research note on Tuesday, January 9th. Piper Jaffray Companies downgraded Fulgent Genetics from an overweight rating to a neutral rating in a research note on Thursday. Finally, Raymond James Financial downgraded Fulgent Genetics from an outperform rating to a mkt perform rating in a research note on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Fulgent Genetics currently has an average rating of Hold and an average target price of $6.50.
Fulgent Genetics (FLGT) traded down $0.49 on Thursday, hitting $3.82. The stock had a trading volume of 26,087 shares, compared to its average volume of 18,264. Fulgent Genetics has a 52 week low of $2.72 and a 52 week high of $11.80.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.